Anti-GTPase HRAS antibody - C-terminal (ab174339)

Overview

  • Product name
    Anti-GTPase HRAS antibody - C-terminal
    See all GTPase HRAS primary antibodies
  • Description
    Rabbit polyclonal to GTPase HRAS - C-terminal
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse
    Predicted to work with: Rat, Chicken, Human
  • Immunogen

    Synthetic peptide within Mouse GTPase HRAS aa 151-179 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary.
    Database link: Q61411

  • Positive control
    • Mouse bladder tissue lysates.

Properties

Applications

Our Abpromise guarantee covers the use of ab174339 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 21 kDa.

Target

  • Function
    Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in disease
    Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similarities
    Belongs to the small GTPase superfamily. Ras family.
  • Post-translational
    modifications
    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localization
    Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links
  • Alternative names
    • C BAS/HAS antibody
    • c H ras antibody
    • C HA RAS1 antibody
    • c has/bas p21 protein antibody
    • c ras Ki 2 activated oncogene antibody
    • c-H-ras antibody
    • CTLO antibody
    • GTP and GDP binding peptide B antibody
    • GTPase HRas, N-terminally processed antibody
    • H Ras 1 antibody
    • H RASIDX antibody
    • H-Ras-1 antibody
    • Ha Ras antibody
    • Ha Ras1 proto oncoprotein antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • Harvey rat sarcoma viral oncogene homolog antibody
    • Harvey rat sarcoma viral oncoprotein antibody
    • HRAS antibody
    • HRAS1 antibody
    • K ras antibody
    • N ras antibody
    • p19 H RasIDX protein antibody
    • p21ras antibody
    • Ras family small GTP binding protein H Ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • Transformation gene oncogene HAMSV antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • VH Ras antibody
    • vHa RAS antibody
    see all

Images

  • Anti-GTPase HRAS antibody - C-terminal (ab174339) at 1/100 dilution + Mouse bladder tissue lysates at 35 µg

    Predicted band size : 21 kDa

References

ab174339 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab174339.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up